Legend Biotech Corporation (LEGN)

Legend Biotech Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	278.89	286.75	1,278	786.03	688.94	455.69
Short-Term Investments	713.7	835.93	30.34	54.02	193.46	50
Trading Asset Securities	-	-	0.66	185.6	-	-
Cash & Short-Term Investments	992.59	1,123	1,309	1,026	882.4	505.69
Cash Growth	-18.13%	-14.21%	27.60%	16.23%	74.49%	218.20%
Accounts Receivable	1.3	6.86	101.43	0.28	50.5	75.62
Other Receivables	201.27	118.03	55.63	44.24	8.04	7
Receivables	202.57	124.89	157.06	44.52	58.55	82.62
Inventory	29.18	23.9	19.43	10.35	1.75	1.8
Prepaid Expenses	17.59	12.37	12.23	17.33	5.72	3.46
Other Current Assets	0.07	0.07	0.36	1.27	1.44	0.38
Total Current Assets	1,242	1,284	1,498	1,099	949.85	593.94
Property, Plant & Equipment	253.74	201.22	189.23	160.76	140.79	111.88
Long-Term Investments	-	4.36	4.36	-	4.71	-
Other Intangible Assets	-	2.16	4.06	3.41	4.68	2.85
Long-Term Accounts Receivable	-	-	-	0.4	-	-
Other Long-Term Assets	217.2	178.49	153.16	67.28	19.44	13.41
Total Assets	1,713	1,670	1,849	1,331	1,119	722.09
Accounts Payable	102.46	38.59	30.66	32.89	7.04	4.91
Accrued Expenses	-	64.51	61.58	152.73	104.38	74.36
Short-Term Debt	-	-	-	-	-	0.33
Current Portion of Leases	7.37	4.79	3.18	3.56	0.91	1.46
Current Income Taxes Payable	10.11	20.67	7.2	9.77	9.49	8.8
Current Unearned Revenue	22.58	47.41	53.08	0.45	0.3	0.28
Other Current Liabilities	148.19	101.67	60.73	98.38	107.08	25.42
Total Current Liabilities	433.57	277.65	216.42	297.79	229.2	115.57
Long-Term Debt	171.93	301.2	281.33	260.93	120.46	-
Long-Term Leases	88.06	44.61	44.17	20.04	1.59	1.91
Long-Term Unearned Revenue	-	6.15	55.27	7.66	1.87	2.05
Long-Term Deferred Tax Liabilities	-	-	-	-	-	4.24
Other Long-Term Liabilities	8.13	-	0.06	0.23	0.4	0.55
Total Liabilities	701.69	629.61	597.24	586.65	353.52	124.32
Common Stock	0.04	0.04	0.04	0.03	0.03	0.03
Additional Paid-In Capital	2,738	2,696	2,637	1,657	1,261	708.31
Retained Earnings	-1,928	-1,662	-1,485	-966.46	-520.11	-116.53
Comprehensive Income & Other	200.63	6.27	98.93	53.72	24.57	5.96
Shareholders' Equity	1,011	1,041	1,251	744.31	765.94	597.77
Total Liabilities & Equity	1,713	1,670	1,849	1,331	1,119	722.09
Total Debt	410.24	350.6	328.67	284.53	122.97	3.7
Net Cash (Debt)	582.35	772.08	980.05	741.12	759.43	501.99
Net Cash Growth	-32.74%	-21.22%	32.24%	-2.41%	51.28%	228.45%
Net Cash Per Share	3.16	4.22	5.57	4.66	5.39	4.25
Filing Date Shares Outstanding	184.69	183.65	181.91	165.07	154.23	133.01
Total Common Shares Outstanding	184.69	183.65	181.91	165.07	154.23	133.01
Working Capital	808.43	1,006	1,281	801.33	720.65	478.38
Book Value Per Share	5.48	5.67	6.88	4.51	4.97	4.49
Tangible Book Value	1,011	1,038	1,247	740.9	761.26	594.92
Tangible Book Value Per Share	5.48	5.65	6.86	4.49	4.94	4.47
Land	-	2.89	2.89	2.89	2.89	2.89
Buildings	-	65.54	65.54	45.08	16.01	11.21
Machinery	-	44.92	45.48	46.26	38.27	29.17
Construction In Progress	-	4.4	3.04	14.18	41.37	27.81
Leasehold Improvements	-	21.28	23.12	21.97	20.91	11.89

Updated Nov 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q